Newswise — The recently reported unsafe medical procedures that infected patients with Hepatitis C at a medical clinic in Las Vegas has left thousands of people wondering if they could be infected. Nearly forty thousand people have visited this clinic that was found to be reusing syringes and vials of medication for nearly four years.

For those covering health and medical news and stories related to Hepatitis C, Samaritan Pharmaceuticals makes available their CEO, Dr. Janet Greeson.

Samaritan knows the severity of hepatitis C and is currently developing a drug to treat the disease. "I have dedicated myself to trying to eradicate diseases," Dr. Greeson states. "To find out that a local clinic where numerous patients like myself were undergoing colonoscopy testing as a precaution against colon cancers, only to then be exposed to possible Hepatitis C infection, concerns me greatly, to say the least."

Hepatitis C (HCV) is characterized by inflammation of the liver, usually producing swelling and, in many cases, permanent damage to liver tissues. HCV is one of the most common types of viral hepatitis. It can lead to long-term, persistent infections, chronic liver disease, and in many cases, even death. Liver failure due to HCV is the leading cause of liver transplants in the United States.

Samaritan is working on a HCV drug, SP-30, that inhibits replication preventing HCV from entering healthy cells. SP-30 appears to be the first true HCV antiviral therapeutic offered for treatment of individuals infected with HCV. In addition to its efficacy, SP-30 appears to have an extremely favorable safety profile, and may offer the convenience of oral dosing in contrast to the standard injectable treatments prescribed today.

Biography of Expert " Dr. Janet Greeson, Samaritan Pharmaceuticals Chairman, President, and CEO

Dr. Janet Greeson, Chairman, President and CEO, led the bold initiative that transformed Samaritan from a "one drug" company to an innovative "Drug Development Pipeline" biopharmaceutical company. She strategically created a long-term value and growth model with the Samaritan/Georgetown University collaboration; a model she has duplicated with McGill University in Montreal, Canada, and intends to implement in other top-tier universities as a solid strategy to continue to build Samaritan's value and sustain its future profitability.

Dr. Greeson is a successful healthcare professional with over two decades of corporate experience focused on emerging growth situations, leadership development, and mergers and acquisitions. Although she has worked with Samaritan for eleven years, as CEO for the past six years she has demonstrated a relentless perseverance and determination to succeed in the face of unrelenting change. She is extremely motivated and equipped to attack problems and seize realistic opportunities, with capability, courage and confidence.

Dr. Greeson is a co-inventor of eighteen patent applications, and presently has nine peer-reviewed journal publications. She is a best selling author of It's Not What You Are Eating, It's What's Eating You; and a renowned public speaker, whose guest appearances on numerous radio and TV Talk shows, has opened the door to tell the Samaritan story, in a concise and professional manner.

Dr. Greeson is an experienced growth "Model" developer. In the past, Dr. Greeson developed model "Addiction Rehab Programs" for the US Navy, and went on privately, to develop and grow a nationwide "inpatient treatment program model" which she later sold to Columbia/HCA (NYSE:COL).

Dr. Greeson has an eclectic past, once working with Mother Theresa and was privileged to be the U.S. Congressional Nominee for the State of Nevada in 1994, winning the primary without spending a dollar to campaign. She currently fulfills her altruistic energies with the Samaritan Innovative Science Foundation.

Dr. Greeson holds a BA from Florida Technological University 1978; an MA from Rollins College 1979; a PhD from Columbia Pacific University 1987.

Dr. Greeson serves as an expert resource on the following:

"¢ Hepatitis C"¢ Antiviral therapeutics"¢ Infectious diseases

Dr. Greeson can address the following FAQs:

"¢ How might clinics ensure patients against the inadvertent infection of Hepatitis C?"¢ What new treatments and procedures are in the pipeline for the treatment and prevention of Hepatitis C and other infectious diseases?

Samaritan Pharmaceuticals is a life science company focused on commercializing its pipeline of innovative drugs to relieve the suffering of patients with Alzheimer's, cancer, heart disease, and infectious disease. Samaritan's business strategy is to partner drug candidates in its pipeline after Phase II (proof of concept) human studies. Samaritan has executed its first partnering agreement with Pharmaplaz, Ireland for its PII, HIV drug SP-01A. In addition, Samaritan's sales arm has acquired the marketing and sales rights to sell ten revenue-generating products in Greece and various Eastern European countries.